INSM
Price
$81.06
Change
-$2.55 (-3.05%)
Updated
Feb 21 closing price
Capitalization
14.67B
67 days until earnings call
INVA
Price
$18.08
Change
+$0.01 (+0.06%)
Updated
Feb 21 closing price
Capitalization
1.13B
One day until earnings call
Ad is loading...

INSM vs INVA

Header iconINSM vs INVA Comparison
Open Charts INSM vs INVABanner chart's image
Insmed
Price$81.06
Change-$2.55 (-3.05%)
Volume$2.72M
Capitalization14.67B
Innoviva
Price$18.08
Change+$0.01 (+0.06%)
Volume$360.04K
Capitalization1.13B
INSM vs INVA Comparison Chart
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INSM vs. INVA commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and INVA is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (INSM: $81.06 vs. INVA: $18.08)
Brand notoriety: INSM and INVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 142% vs. INVA: 62%
Market capitalization -- INSM: $14.67B vs. INVA: $1.13B
INSM [@Biotechnology] is valued at $14.67B. INVA’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileINVA’s FA Score has 0 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • INVA’s FA Score: 0 green, 5 red.
According to our system of comparison, INSM is a better buy in the long-term than INVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 6 TA indicator(s) are bullish while INVA’s TA Score has 2 bullish TA indicator(s).

  • INSM’s TA Score: 6 bullish, 4 bearish.
  • INVA’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, INSM is a better buy in the short-term than INVA.

Price Growth

INSM (@Biotechnology) experienced а +2.21% price change this week, while INVA (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

INSM is expected to report earnings on May 01, 2025.

INVA is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($14.7B) has a higher market cap than INVA($1.13B). INSM YTD gains are higher at: 17.410 vs. INVA (4.207). INVA has higher annual earnings (EBITDA): 123M vs. INSM (-769.56M). INSM has more cash in the bank: 1.47B vs. INVA (261M). INVA has less debt than INSM: INVA (451M) vs INSM (1B). INVA (353M) and INSM (343M) have equivalent revenues.
INSMINVAINSM / INVA
Capitalization14.7B1.13B1,299%
EBITDA-769.56M123M-626%
Gain YTD17.4104.207414%
P/E RatioN/A22.60-
Revenue343M353M97%
Total Cash1.47B261M562%
Total Debt1B451M222%
FUNDAMENTALS RATINGS
INSM vs INVA: Fundamental Ratings
INSM
INVA
OUTLOOK RATING
1..100
1980
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
1260
SMR RATING
1..100
10069
PRICE GROWTH RATING
1..100
3856
P/E GROWTH RATING
1..100
10039
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INVA's Valuation (64) in the Pharmaceuticals Other industry is in the same range as INSM (88) in the Biotechnology industry. This means that INVA’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (12) in the Biotechnology industry is somewhat better than the same rating for INVA (60) in the Pharmaceuticals Other industry. This means that INSM’s stock grew somewhat faster than INVA’s over the last 12 months.

INVA's SMR Rating (69) in the Pharmaceuticals Other industry is in the same range as INSM (100) in the Biotechnology industry. This means that INVA’s stock grew similarly to INSM’s over the last 12 months.

INSM's Price Growth Rating (38) in the Biotechnology industry is in the same range as INVA (56) in the Pharmaceuticals Other industry. This means that INSM’s stock grew similarly to INVA’s over the last 12 months.

INVA's P/E Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for INSM (100) in the Biotechnology industry. This means that INVA’s stock grew somewhat faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMINVA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
38%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
67%
Momentum
ODDS (%)
Bullish Trend 6 days ago
77%
Bearish Trend 3 days ago
67%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
61%
Advances
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 3 days ago
69%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 6 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 6 days ago
50%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
69%
View a ticker or compare two or three
Ad is loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VICAX20.94-0.07
-0.33%
USA Mutuals Vice A
DOXBX106.83-0.53
-0.49%
Dodge & Cox Balanced X
MWEBX39.70-0.31
-0.77%
MFS Global Equity B
GPEOX11.82-0.13
-1.09%
Grandeur Peak Emerg Mkts Opps Inv
PXQSX25.40-0.43
-1.66%
Virtus KAR Small-Cap Value I

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
-3.05%
THAR - INSM
74%
Closely correlated
+1.99%
SRPT - INSM
44%
Loosely correlated
-1.96%
AGIO - INSM
41%
Loosely correlated
+4.36%
VERA - INSM
41%
Loosely correlated
-3.48%
AXON - INSM
40%
Loosely correlated
-5.28%
More

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with SGMO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then SGMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
+0.06%
SGMO - INVA
40%
Loosely correlated
-4.46%
DTIL - INVA
34%
Loosely correlated
+0.68%
INSM - INVA
33%
Loosely correlated
-3.05%
VXRT - INVA
33%
Poorly correlated
+1.21%
REGN - INVA
32%
Poorly correlated
+0.62%
More